Share
3,848 Posts.
lightbulb Created with Sketch. 1920
clock Created with Sketch. 06/06/24
21:51
Share
Originally posted by Flectional:
↑
your take is interesting in a number of areas - and not accurate dcPsiGAD-1 is a randomised triple-blind active-placebo-controlled Phase 2 trial. The primary objective of the study is to determine whether a 7-week program of psilocybin-assisted psychotherapy for GAD is superior to active placebo-assisted psychotherapy in decreasing symptoms of GAD, as measured by the change in the Hamilton Anxiety Rating Scale (HAM-A) from baseline to week 11. Safety and tolerability were assessed, as well as other secondary objectives of efficacy and quality of life.
Expand
Also @Flectional , the FDA gave IHL's GAD-PSI program approval for further development PRE-IND. Lycos got the thumbs down. A credit to the Manarsh team.
